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ABSTRACT
Infection of Hantaan virus (HTNV) usually causes hemorrhagic fever with renal 
syndrome (HFRS). China has the worst epidemic incidence of HFRS as well as high 
fatality. Inactivated whole virus has been used for HFRS vaccination, however there 
are still problems such as safety concerns. CD40 ligand (CD40L) and granulocyte 
macrophage colony-stimulating factor (GM-CSF) are well-known immune stimulating 
molecules that can enhance antigen presenting, lymphocytes activation and 
maturation, incorporation of CD40L and GM-CSF to the surface of virus like particles 
(VLPs) can greatly improve the vaccination effect. We constructed eukaryotic vectors 
expressing HTNV M segment and S segment, as well as vectors expressing HTNV M 
segment with CD40L or GM-CSF, our results showed successful production of CD40L or 
GM-CSF incorporated HTNV VLPs. In vitro stimulation with CD40L or GM-CSF anchored 
HTNV VLP showed enhanced activation of macrophages and DCs. CD40L/GM-CSF 
incorporated VLP can induce higher level of HTNV specific antibody and neutralizing 
antibody in mice. Immunized mice splenocytes showed higher ability of secreting 
IFN-γ and IL-2, as well as enhancing CTL activity. These results suggest CD40L/GM-
CSF incorporated VLP can serve as prospective vaccine candidate.
INTRODUCTION
Infectious Hantaan virus (HTNV) is a major cause 
of hemorrhagic fever with renal syndrome (HFRS). In 
China, it refers to about 100,000 of patients every year 
[1]. Inactivated whole HTNV viron has been used for 
HFRS vaccination, and the outcome is encouraging [2]. 
However the inactivated vaccine still has problems with 
less than satisfactory levels of neutralizing antibody titer 
and activation of cellular immunity. In addition there 
are also safety concerns with bringing in animal-derived 
virus or virulence restoration [3]. Therefore, development 
of new type of HFRS virus vaccine is imminent for the 
control of HFRS.
HTNV viral genome contains three fragments, L, 
M and S, which encode RNA depended RNA polymerase 
(RdRp), membrane glycoprotein (GP, GP is further cleaved 
into Gn and Gc) and nucleoprotein (NP) respectively [4]. 
Both GP and NP are the main immune response eliciting 
structural proteins. GP is responsible for viral entry [5] 
and is able to induce neutralizing antibodies that , facilitate 
protective immune response, but its immunogenicity 
is relatively weaker [6]. NP has several T cell epitopes 
and has strong immunogenicity [7], however the ability 
to induce neutralizing antibodies is lower. Virus like 
particles (VLPs) that mimic natural virus can provide a 
way to combine both GP and NP to boost both humoral 
and cellular immune response.
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VLPs usually emerge in natural virus life cycles, 
which consist of viral structural protein [8]. The formation 
of VLPs can be achieved by simply expressing one or 
several factors like structural proteins [9], and can be 
genetically altered to insert foreign gene and display 
desired molecular on the surface [10, 11], they are 
widely used in researches of vaccines and mechanism 
of virus infection. The VLP approach appears promising 
and advantageous over many other structural forms of 
vaccines [12-14]. VLPs have been found to provide 
high immunogenic potency in protecting against various 
pathogens, such as human papillomavirus. The FDA 
approved HPV vaccine Cervarix® and Gardasil® are 
composed of VLPs which can provide cross protection 
for different HPV serotypes, also induce ten times higher 
neutralizing antibodies than natural infection [15, 16]. 
Although those are the only two approved VLP vaccines 
nowadays, there are many more in development [17].
It has been mentioned above that the expression of 
M segment in host cells can lead to production of VLPs 
that were composed of spherical membrane vesicles, with 
or without nucleocapsid, similar to the morphology of 
natural virions, but we need VLPs with full components 
in order to elicit both neutralizing antibodies and virus-
specific cytotoxic T lymphocytes. In order to enhance the 
immunogenicity, the gene expressing VLPs can be altered 
to display non-structural proteins such as cytokines and 
specific antigens [18] that usually won’t abrogate the 
expression of structural protein. CD40L and GM-CSF 
are usually used to enhance immune effect of vaccines 
[19]. CD40L is a key activator of immune response by 
engaging CD40 on the B cell surface and therefore 
facilitating immunoglobulin class switching and affinity 
maturation, which is an important process of adaptive 
immune response [20, 21]. GM-CSF is identified as an 
inducer of differentiation and proliferation of granulocytes 
and macrophages derived from hematopoietic progenitor 
cells, it also involves an adaptive immunity by activation 
of dendritic cells [22]. Both CD40L and GM-CSF is able 
to facilitate anti-viral immunity, so we choose the two 
factors to construct recombinant VLPs.
In this study we constructed plasmids containing 
HTNV M segment and CD40L/GM-CSF gene, co-
transfected with vector containing S segment into dhfr- 
CHO and obtained HTNV VLPs anchoring CD40L or 
GM-CSF, the protein composition and the structure 
were verified by Western blot. In vitro stimulation with 
CD40L or GM-CSF anchored HTNV VLP showed 
enhanced activation of macrophages and DCs. Data of 
animal research suggest that humoral immune responses 
and cellular immunity induced by CD40L or GM-CSF 
decorated HTNV VLP were superior to undecorated 
VLPs as well as HTNV vaccine, and able to reduce viral 
load in immunized mice. These results indicated that the 
recombinant HTNV VLP could be a promising vaccine 
candidate.
RESULTS
CD40L/GM-CSF and HTNV GP can be 
expressed by co-transfection of pCI-S and pCI-
M-CD40L, pCI-S and pCI-M-GM-CSF
In order to express CD40L/GM-CSF in cis along 
with HTNV antigens, we developed the VLPs by inserting 
the membrane bound form of a murine CD40L/GM-CSF 
gene downstream of the HTNV M gene of our plasmid 
that expresses HTNV GP. We verified the plasmid by 
nucleic acid electrophoresis and bands can be seen at 780 
bp, and 530 bp (Supplementary Figure S1A), 1.3 kb, 3.4 
kb (Supplementary Figure S1B), corresponding with the 
length of S, M, CD40L and GM-CSF gene. The plasmids 
were further verified by DNA sequencing (Supplementary 
Figure S2). Indirect immune fluorescence analyses showed 
that the HTNV GP and CD40L/GM-CSF were expressed 
on the cell membrane after transfection (Figure 1). These 
results showed that CD40L/GM-CSF and HTNV GP could 
be expressed by co-transfection of plasmid pCI-S and pCI-
M-CD40L, pCI-S and pCI-M-GM-CSF, which are used in 
further study.
The morphology and protein composition of the 
VLPs is verified
We produced HTNV VLPs in dhfr- CHO cells by 
co-transfected with pCI-S and pCI-M, pCI-S and pCI-
M-CD40L, pCI-S and pCI-M-GM-CSF. Purified HTNV 
VLPs exhibited a consistent size of approximately 100 
nm under transmission electron microscopy, in addition, 
HTNV VLPs were spherical and pleomorphic both in 
transfected cells (Figure 2A) and culture supernatants 
(Figure 2B). Purified HTNV VLPs proteins were 
confirmed using SDS-PAGE, Coomassie Blue-stained 
gels and Western blots. The expected molecular weights 
of Gn, Gc, NP and CD40L/GM-CSF (70, 55, 48 and 
37.5/29kDa, respectively) were observed in purified 
HTNV VLPs (Figure 2C, 2D). All the VLPs got desired 
composition both in morphology and protein composition 
after purification.
CD40L/GM-CSF HTNV GP were coexpressed
We probed VLPs by indirect ELISA analysis, and 
CD40L/GM-CSF can be detected by Gn or Gc capture 
antibodies (Figure 3A). Similar results were obtained with 
NP specific monoclonal antibodies as capture antibodies 
(Figure 3B). The positive/negative (P/N) value of CD40L-
VLP group and GM-CSF group is significantly higher than 
the control group (p<0.001). Immunoprecipitation (IP) 
showed similar results that CD40L/GM-CSF can be pulled 
down with Gn monoclonal antibodies (Figure 3C). These 
results suggest that the VLPs we constructed had desired 
protein colocalization, and were structurally intact.
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CD40L-VLP and GM-CSF-VLP promote 
differentiation of bone marrow-derived 
macrophages and dendritic cells in vitro
We separated bone marrow cells from healthy 
C57BL/6 mice and stimulated with CD40L-VLP, GM-CSF-
VLP, undecorated VLP (VLP) and M-CSF/GM-CSF as 
positive controls.As shown in Figure 4, the cell population of 
F4/80+CD11b+ in the GM-CSF-VLP and CD40L-VLP group 
(89.5% and 74.6%) are significantly higher than in the VLP 
group (68.4%) (p=0.0065) (Figure 4A), which indicated the 
differentiation towards bone marrow derived macrophages 
(BMDM). Meanwhile, the positive rate of bone marrow cells 
stimulated by CD40L/GM-CSF decorated VLPs showed 
significantly higher up-regulation of CD11c (29.0% and 
41.0%) and MHC-II (12.6% and 17.0%) than the VLP group 
(1.9% for CD11b and 5.9% for MHC-II) (p<0.0001) (Figure 
4B) which are markers for DCs (Figure 4C). These results 
indicate that CD40L/GM-CSF decorated HTNV VLPs have 
the potential of promoting the differentiation of bone marrow 
cells towards macrophages and DCs.
CD40L-VLP and GM-CSF-VLP induced higher 
virus antigen specific antibodies and neutralizing 
antibodies as well as switching amongst antibody 
subtypes
Purified recombinant VLPs antigens were tested 
for the ability to induce specific antibodies against each 
HTNV NP antigen by ELISA. Sera were obtained from 
each immunized mice and tested to assess HTNV antigen 
specific antibodies. NP or GP specific antibody titers were 
higher after immunization with CD40L-VLP compared 
to other VLP groups and vaccine group (p=0.0022 for 
NP and p=0.0015 for GP). However, GM-CSF-VLP 
group did not have advantage over undecorated VLP 
groups (p=0.1038 for NP and p=0.0928 for GP), but got 
advantage over vaccine and saline controls (p=0.0003 for 
NP and p=0.0004 for GP) (Figure 5A). We did not detect 
specific antibodies in saline control group. The Geometry 
mean titer of each group was listed (Table 1).
Neutralizing antibody responses to HTNV were 
determined by ELISA analysis of the sera from immunized 
mice in order to evaluate the effective humoral immune 
response induced by the VLPs. There is no significant 
difference amongst VLP group and VLP co-immunized 
with CD40L/GM-CSF (p=0.2567). Compared with vaccine 
group and saline control, the geometric mean for the 
neutralizing antibody titer of the CD40L-VLP/GM-CSF-
VLP were significantly higher (p=0.0003 for CD40L-VLP 
and p=0.0002 for GM-CSF-VLP) (Figure 5B). The mean 
for neutralizing antibody titer of the CD40L-VLP group 
and GM-CSF-VLP group was 251.9 and 200.0, which was 
higher than that of the undecorated VLP group (p=0.0113 
for CD40L-VLP and p=0.0185 for GM-CSF-VLP). Sera 
from CD40L or GM-CSF immunized simultaneously with 
undecorated HTNV VLP mice showed similar neutralizing 
antibody titer with undecorated VLP group. These results 
Figure 1: Verification of plasmids. Co-transfection of pCI-S and pCI-M-CD40L, pCI-S and pCI-M-GM-CSF into dhfr deficient CHO 
cells and the expression of GP, CD40L and GM-CSF were tested using GP specific monoclonal antibody (mouse) and CD40L/GM-CSF 
polyclonal antibody (rabbit). Then the cells subjected to goat anti mouse or goat anti rabbit fluorescence antibody. DAPI was used for 
nucleus staining.
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Figure 2: Verification of the morphology and protein composition of VLPs. A. Dhfr deficient cells co-transfected with pCI-S 
and pCI-M-CD40L, pCI-S and pCI-M-GM-CSF were harvested and fixed with wax and sliced for electron microscopy. VLPs were observed 
besides cells ranged 50-100 nm in diameter. Each bar at the bottom indicates 100 nm. B. Purified VLPs were dropped onto bronze nets and 
stained with phosphoric acid, and then subjected to electron microscopy. VLPs ranged 80-120 nm in diameter were observed. Each bar at 
the bottom indicates 100 nm. C. Purified HTNV VLP, CD40L-VLP and GM-CSF-VLP were subjected to SDS-PAGE under 160 V for 45 
min, and then stain with Coomassie blue. Bands locate at 70 kDa (Gn), 55 kDa (Gc), 48 kDa (NP), 37.5 kDa (CD40L) and 29 kDa (GM-
CSF) can be observed. D. Purified HTNV VLP, CD40L-VLP and GM-CSF-VLP were subjected to SDS-PAGE under the same condition 
with (B), and then transferred to PVDF membrane. The membrane was then incubated with a mixture of GP monoclonal antibody and 
CD40L/GM-CSF polyclonal antibody. Corresponding secondary antibodies were incubated and scanned with a infrared imager.
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Figure 3: Verification of the co-localization of HTNV structural protein and CD40L/GM-CSF. A. ELISA assay of purified 
VLPs. The 96-well plates were coated with Gn or Gc antibodies and detected with CD40L or GM-CSF antibody, the error bar is shown on 
the top of each bar. B. ELISA assay of purified VLPs. The 96-well plates were coated with NP specific antibody (1A8) or CD40L/GM-CSF 
specific antibodies (CD40L Ab/GM-CSF Ab) and detected with antibodies to CD40L or GM-CSF, the error bar is shown on the top of each 
bar. C. Western blot of samples of immunoprecipitation. CD40L (i) or GM-CSF (iii) was pulled down by Gn specific antibody and band 
of CD40L and GM-CSF can be seen at 37.5 kDa and 29kDa on PVDF membrane. Gn can also be pulled down by CD40L or GM-CSF 
antibodies, band of Gn can be seen at 70 kDa (ii iv).
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Figure 4: flow cytometry assay of macrophages and DCs stimulated by CD40L-VLP or GM-CSF-VLP. Bone marrow 
cells were separated from healthy C57BL/6 mice and stimulated with CD40L-VLP, GM-CSF-VLP, undecorated VLP (VLP) and a M-CSF/
GM-CSF positive control. A. The percentage of CD11b+ F4/80+ cell population of bone marrow cells stimulated by M-CSF, undecorated 
VLP (VLP), GM-CSF-VLP and CD40L-VLP respectively. B. The positive rate of CD11C and MHC-II of bone marrow cells stimulated 
with GM-CS, CD40L-VLP, GM-CSF-VLP or VLP. C. Quantitative analysis for (A) and (B)
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Figure 5: Detection of HTNV specific antibodies and antibody subtypes. 7 days after the last immunization, sera from the 
mice were collected and subjected to A. HTNV GP or NP specific antibody detection by ELISA. 96-wells plates were coated with full 
length Gn and Gc or NP, a HRP conjugated goat anti mouse IgG antibody was used for detection of specific antibody in the sera. B. Sera 
from immunized mice were serial diluted and incubated with infectious HTNV before added to Vero E6 cells. 10 days later the cells were 
subjected to freeze/thaw cycles and the supernatant was collected for detection of HTNV virions by ELISA. The Geometry mean titer of 
neutralizing antibody titer was calculated. C. Sera from each group of mice were tested for immunoglobulin subtypes by ELISA. HRP 
conjugated goat anti mouse IgG1, IgG2a and IgG2b antibodies were used for detection. The relative values of absorbance at 450 nm of 
IgG2a to IgG1 (IgG2a/IgG1) was calculated, the values of absorbance at 450 nm of IgG2b was directly shown.
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suggested that immunization with recombinant VLPs can 
induced stronger neutralizing antibody responses than 
immunization with monovalent VLPs. The Geometry 
mean titer of each group was listed (Table 2).
Sera from immunized mice were tested for HTNV 
NP specific antibody subtypes by sandwich ELISA. We 
detected IgG1, IgG2a, IgG2b, IgA and IgM. The ratio 
of IgG2a/IgG1 is an indicator of humoral protective 
effect after viral infection. Sera from mice, which were 
immunized with CD40L-VLP or GM-CSF-VLP showed 
higher IgG2a compared to undecorated VLPs (p=0.0031 
for CD40L-VLP and p=0.0033 for GM-CSF-VLP), 
however sera from vaccine group and PBS control showed 
higher IgG1. Though there were differences in IgG2b, the 
overall level of this subtype is low (Figure 5C). We also 
tested levels of IgA and IgM from sera of immunized 
mice, but there were no significant difference amongst 
VLP and vaccine group (p=0.3835 for IgA and p=0.4339) 
(Supplementary Figure S3). These results indicate that 
CD40L-VLP and GM-CSF-VLP may be able to switch 
immunoglobulin into specific subtypes.
CD40L-VLP and GM-CSF-VLP promote anti-
viral cytokines release and CTL response
Spleen cells were isolated on day 34 (7 days after the 
last immunization) to assess the cellular immune response 
to the recombinant HTNV VLP. IFN-γ, IL-2, IL-4 and IL-10 
cytokine were analyzed by ELISPOT, following stimulation 
with HTNV GP or NP peptides. There was no significant 
difference in levels of IFN-γ and IL-2 from undecorated 
VLP groups compared to inactivated HTNV virion vaccine 
group (p>0.05). The number of splenocytes secreting IFN-γ 
and IL-2 were higher in the CD40L or GM-CSF decorated 
VLP group compared to the vaccine group (Figure 6A, 6B). 
The overall amount of IL-10 and IL-4 secreting cells were 
small in all groups, however greater than the PBS control 
group; there was no significant difference in all VLP groups 
and vaccine group (Supplementary Figure S4). These 
results indicate that CD40L-VLP and GM-CSF-VLP may 
direct immune response towards Th1 type.
Macrophages could be infected by HTNV, which 
were used as target cells by immune fluorescence assay 
(Supplementary Figure S5), HTNV antigen can be observed 
on the membrane of macrophages and more than 90% of 
them were infected. Percentage of specific lysis of target 
cells was calculated and GM-CSF-VLP showed highest 
lysis activity stimulated by NP peptide. CD40L-VLP 
showed relatively moderate lysis activity. CD40L-VLP 
group showed significant difference compared to VLP 
groups under 100:1, 50:1 and 25:1 E/T (p<0.001, p<0.01 
and p<0.01), when stimulated by NP peptide pool, but 
had no advantage over CD40L co-immunization group 
(p>0.05). When stimulated by GP peptide pool, CD40L-
VLP showed advantage over VLP groups only under 100:1 
E/T (p<0.0001). Under 100:1 E/T, GM-CSF-VLP group 
showed significant difference either compared with VLP 
groups (p<0.001) or with vaccine/saline control groups 
(p<0.001) when stimulated by GP peptide pool. When 
stimulated by NP peptide pool, GM-CSF-VLP showed 
advantage over any other group under 100:1, 50:1 and 25:1 
E/T (p<0.001, p<0.001 and p<0.001) (Figure 6C). These 
results indicated that cellular immune response could be 
effectively induced by CD40L-VLP and GM-CSF-VLP, 
though CD40L-VLP induction was relatively moderate.
Protection of mice from viral challenge
We tested the protection ability provided by VLPs 
by challenging immunized mice with infectious HTNV. 
Three days after viral challenge, the viral load of heart, 
liver, spleen, lung, kidney and cerebrum were tested by 
sandwich ELISA as well as qRT-PCR. We detected small 
amount of viral antigen (Figure 7A) and RNA (Figure 
7B) exist in liver from all groups, however the amount 
of virus in spleen, lung, kidney and cerebrum were 
Table 1: Geometry mean titer of NP or GP specific antibody in the sera of immunized mice
Groups NP specific (GMT) GP specific (GMT)
CD40L-VLP 142.5 100.8
GM-CSF-VLP 80 50.4
VLP 40 31.7
CD40L+VLP 50.4 44.9
GM-CSF+VLP 50.4 56.6
Vaccine 20 20
Saline -- --
NP or GP specific antibody titers obtained from ELISA were calculated for geometry mean titer. NP specific stands for 
HTNV NP specific antibody, GP specific stands for HTNV GP specific antibody. CD40L-VLP or GM-CSF-VLP stand 
for HTNV VLP decorated with CD40L or GM-CSF, CD40L+VLP or GM-CSF+VLP stand for CD40L or GM-CSF co-
immunize with HTNV VLP.
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significantly lower in CD40L-VLP (p<0.0001 for heart, 
p<0.01 for spleen, p<0.001 for lung, p=0.001 for kidney 
and p=0.001 for cerebrum) and GM-CSF-VLP (p<0.0001 
for heart, p<0.01 for spleen, p<0.001 for lung, p<0.001 for 
kidney and p<0.001 for cerebrum) groups. PBS control 
group showed highest amount of viral load. These results 
indicate that immunization of the recombinant VLPs can 
provide protection against HTNV challenge by reducing 
viral load.
DISCUSSION
VLPs have similar structural and physicochemical 
features with origin virions, however they are non-
infectious and possess advantages in terms of safety and 
manufacturing [23]. One of the important characteristics 
of VLPs is that they can elicit strong humoral and cellular 
immune responses against viruses. Recombinant Hantaan 
virus VLPs have been shown to be able to be efficiently 
produced by expression of M segment, either with or 
without nuclear proteins [9], but VLPs with full components 
may elicit stronger immune response. Our previous study 
demonstrated that the reconstructed pCI-neo plasmid can be 
used in protein expression by CHO cells (data unpublished). 
In this study, the reconstructed pCI-neo was applied to 
recombinant VLP production and the immunogenicity and 
protective effect of the VLPs were evaluated.
To ensure the expression of VLPs, we used a dhfr 
gene deficient CHO cell line, which cannot survive 
in medium without hypoxanthine and thymine (HT) 
supplement. The pCI-S-neo and pCI-M-CD40L/GM-CSF 
plasmid contain two parts of dhfr gene, only when the two 
plasmids are correctly transfected can the deficient cells 
survive in medium without HT. The dhfr deficient CHO 
cells are sensitive to G418, but pCI-S-neo can provide 
G418 resistance, that is to say, correctly transfected 
cells can survive in medium containing G418. We also 
applied MTX in culture medium, which can suppress 
the expression of dhfr gene; it must be amplified to keep 
cells alive. CD40L/GM-CSF was located downstream of 
dhfr, the amplification can spur the expression of CD40L/
GM-CSF. These measurements can ensure the correct 
expression of all components of the VLPs we needed. In 
vitro stimulation with CD40L/GM-CSF decorated VLPs 
was able to promote bone marrow cells towards DCs and 
macrophage lineage, which indicate that VLPs had desired 
construction and basic function.
The analysis of humoral immune responses revealed 
that antigen specific IgG CD40L-VLP and GM-CSF-VLP 
induced were higher than that of undecorated VLPs, and 
even higher than HTNV vaccine used in clinical practice. 
We also found that antibody subtypes changed in sera from 
immunized mice, CD40L-VLP and GM-CSF-VLP had 
highest ratio of IgG2a/IgG1, revealing the anti-viral ability 
of antibodies is high in vivo [24, 25]. Neutralizing antibody 
assay further proved this observation. VLPs can not only 
improve antibody production, but also enhance cellular 
immunity. In our study, anti-viral cellular immune responses 
were assessed by the number of VLP-stimulated spleen 
cells that release IFN-γ, IL-2, IL-4 and IL-10. The number 
of IFN-γ and IL-2 secreting splenocytes was significantly 
higher in mice that received CD40L or GM-CSF decorated 
VLPs compared to vaccine group and PBS controls. 
However, neither IL-4 nor IL-10 secreting splenocytes were 
significantly higher in all VLP groups. IFN-γ is a type of 
Th1 cytokine, which has an anti-viral effect, we can infer 
that the immunization of VLP may alter the tendency of 
immune response to Th1 [26], the low level of IL-4 and IL-
10 secretion proved this hypothesis [27]. However, many 
other cytokine/chemokines are considered to be correlated 
with Hantaan virus related disease, including IL-2, IL-6, 
IL-8, IL-10, IFN-γ, TNF, and the intensity of platelet β3 
integrin [28-34]. Results of the current study are not enough 
to evaluate Th1 or Th2 immune responses produced by 
CD40L or GM-CSF decorated VLPs or the corresponding 
dynamic variation. Further studies of T-cell responses are 
needed to understand the immune status of mice immunized 
with the recombinant HTNV-VLP.
Table 2: Geometry mean titer of neutralizing antibody in the sera of mice
Groups Neutralizing antibody (GMT)
CD40L-VLP 251.9
GM-CSF-VLP 200
VLP 116.9
CD40L+VLP 100
GM-CSF+VLP 100
Vaccine 80
Saline --
Neutralizing antibody titers obtained from ELISA were calculated for geometry mean titer. CD40L-VLP or GM-CSF-VLP 
stand for HTNV VLP decorated with CD40L or GM-CSF, CD40L+VLP or GM-CSF+VLP stand for CD40L or GM-CSF 
co-immunize with HTNV VLP.
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Figure 6: ELISPOT and CTL assay of splenocytes from immunized mice. 7 days after the last immunization, splenocytes of 
the mice were isolated and stimulated with NP or GP peptide pool, each pool contain peptides of 15 amino acid residues with 8 overlaps. 
The splenocytes were tested for secretion of A. IL-2 through spot formation. B. Splenocytes from immunized mice were stimulated with 
the same peptide pool along with IFN-γ.C. HTNV infected macrophages from healthy mice were used as target cells. A serial of numbers 
of stimulated splenocytes were incubated with target cells for 6 h before the LDH release was assessed.
Oncotarget63498www.impactjournals.com/oncotarget
Figure 7: Detection of viral load in main organs after virus challenge. 3 days after virus challenge of immunized mice, primary 
organs of all groups of mice were collected and grinded for HTNV specific antigen detection. A. The samples were subjected to freeze/
thaw cycles and the supernatant were collected for ELISA. The level of NP protein was shown on the graph. B. Total RNA was extracted 
and reverse transcripted to cDNA. We used a S segment specific primer for detection of HTNV specific sequence, the relative quantity is 
show on the graph.
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The protective efficacy of the VLPs was tested by 
viral challenge of immunized mice. The results showed 
that immunization with either CD40L-VLP or GM-
CSF-VLP conferred the most protection, against HTNV 
challenge, which has the least viral load in important 
organs. However histopathological analysis show little 
difference in numbers of lymphocytes except in spleen. 
This is probably because HTNV can only infect adult 
mice causing no pathological events and we intend to use 
suckling mouse to assess the protection effect of the VLPs 
in our further study.
In conclusion, the construction of a recombinant 
HNTV VLP vaccine candidate, based on dhfr deficient 
CHO cells and the immune effect of the VLPs is 
described. We successfully produced VLPs with desired 
protein components and construction. The CD40L or GM-
CSF decorated VLP induced stronger humoral immune 
responses against HTNV as well as cellular immunity. 
Moreover, protective efficacy in mice was better with 
the CD40L or GM-CSF decorated VLP than with the 
vaccine. Further study is needed to adjust the productivity 
of the VLP producing dhfr- CHO cells and to clarify the 
protective efficacy of that is induced.
MATERIALS AND METHODS
Cells and viruses
Dihydrofolatereductase deficient CHO cells (dhfr- 
cells, purchased from Culture Collection of Chinese 
Academy of Science, Shanghai) were maintained in 37°C 
with 5% CO2 in ISCOVE’s modified DMEM (IMDM) 
(Gibco) supplemented with 10% fetal bovine serum 
(Gibco), 2% HT mix (Sigma), and 100nM methotrexate 
(MTX) (Sigma). Mouse macrophage cells and bone 
marrow cells were separated from healthy C57BL/6 mice 
and similarly cultured in DMEM supplemented with 10% 
FBS. HTNV strain 76118 was kept in our lab, and all 
related experiments were performed in a biosafety level 
2 (BSL-2) setting.
Construction of CD40L or GM-CSF anchored 
VLP expressing plasmid
Genes encoding HTNV M, HTNV S segments 
were cloned into pCI-neo plasmid, which was provided 
by professor Yan Yan. We named the recombinant 
plasmid as pCI-S and pCI-M. pCI-M was digested 
with StuI and BstBI and then mouse CD40L gene 
was cloned into the plasmid. Mouse GM-CSF-GPI 
gene was similarly cloned into pCI-M using StuI and 
BstXI. The plasmids containing CD40L and GM-CSF 
gene were named as pCI-M-CD40L and pCI-M-GM-
CSF respectively. Nucleic acid electrophoresis and 
DNA sequencing verified the construction of the four 
plasmids.
Indirect fluorescence assays (IFAs) were performed 
to assess the expression of GP, CD40L and GM-CSF. Dhfr- 
cells were cotransfected with pCI-S and pCI-M, pCI-S 
and pCI-M-CD40L, pCI-S and pCI-M-GM-CSF. The 
cells were cultured at 37°C for 48h. Supernatants were 
discarded, and the cells were fixed with 0.4% polysorbate 
at room temperature for 15 min. Cells were then washed 
in PBS (0.01mol/L) and treated with 0.5% Triton-X100 
at room temperature for 15 min. After washing with PBS, 
mouse anti HTNV Gc monoclonal antibody and rabbit anti 
CD40L or GM-CSF polyclonal antibodies were incubated 
with fixed cells at 37°C for 1h. Cells were then washed 
with PBS and incubated with FITC-conjugated goat anti-
mouse and Cy3-conjugated goat anti-rabbit secondary 
antibody at 37°C for 1h. DAPI was used for nuclear dye. 
Finally, the cells were washed with PBS and observed 
using fluorescence microscopy.
VLP production and purification
Dhfr- cells were cotransfected with pCI-S and 
pCI-M, pCI-S and pCI-M-CD40L, pCI-S and pCI-M-GM-
CSF respectively. The cells were cultured for 24h after 
transfection, and then cells were carefully washed with 
DPBS before replacing culture medium with serum-free 
CHO medium (Hyclone). Supernatants were collected 72h 
after transfection. Culture supernatants containing VLPs 
were harvested and clarified by low-speed centrifugation at 
1000rpm for 10 min at 4°C followed by ultracentrifugation 
at 30,000rpm for 60 min to pellet. Sedimented particles 
were suspended in phosphate-buffered saline (PBS) at 
4°C.
Verification of VLPs
Characterization of HTNV VLPs GP, NP and CD40L 
or GM-CSF was performed using a sodium dodecyl 
sulfate (SDS) 10% polyacrylamide gel; Coomassie stain 
and Western blot analysis. Total VLP protein amounts 
of 10µg, were loaded into the gel and transferred onto 
a PVDF membrane using a Mini Trans-Blot (Bio-Rad, 
CA). Membranes were blocked using 5% BSA at room 
temperature for 1h and then incubated with HTNV Gc 
monoclonal antibody and CD40L or GM-CSF polyclonal 
antibodies overnight at 4°C. Membranes were washed 
with PBS containing 0.5% tween-20 (PBST), and then 
incubated with infrared conjugated antibody and proteins 
were visualized using an infrared imaging system.
Coexpression of HTNV GP and CD40L or GM-
CSF was examined by ELISA. We coated a 96-well plate 
with Gn or Gc monoclonal antibodies at 4°C overnight, 
the plate was washed with PBST, then samples containing 
CD40L-VLP and GM-CSF-VLP were addes into the plate 
and incubated at 37°C for 1 h. Anti CD40L or GM-CSF 
antibody was added into the plate and incubated at 37°C 
after washing with PBST. The uncombined antibodies 
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were washed away and HRP conjugated secondary 
antibodies were added. After incubation at 37°C for 
1h, TMB solution was added and 450nm absorbance 
was detected. The coexpression was further tested by 
immunoprecipitation. Purified CD40L-VLP and GM-CSF-
VLP were incubated with CD40L/GM-CSF antibody or 
Gn antibody at 4°C overnight. Then we used Protein G 
beads to capture the antibodies. The samples were boiled 
with SDS and the beads were discarded before they were 
subjected to Western blot.
Electron microscopy
Dhfr- CHO cells cotransfected with pCI-S and 
pCI-M, pCI-S and pCI-M-CD40L, pCI-S and pCI-M-GM-
CSF expressing HTNV-VLP, CD40L-VLP and GM-CSF-
VLP respectively, were fixed with 1% phosphotungstic 
acid for 1-2 min to examine the budding of VLPs at 
200,000×. Supernatant was dropped onto a piece of bronze 
net and excess stain was wicked away. The samples were 
air dried for 1-3 min. VLPs were observed using a H8100 
transmission electron microscope at a magnification of 
300,000X.
Determination of in vitro activity of VLPs
Bone marrow was flushed from femurs and tibias 
from healthy C58BL/6 mice. A total of 1× 106/well 
nucleated cells were added to 6-well tissue culture plates 
and cultured in 1 mL of RPMI1640 medium containing 
10% FCS. Then the VLPs were added to observe 
differentiation toward macrophage/DCs lineage that was 
compared with M-CSF or GM-CSF positive control. After 
6 days in culture, contaminating non-adherent cells are 
eliminated and adherent cells are harvested for BMDM 
assays.. Cells were cultured for 6 d and then harvested for 
flow cytometry. Population of macrophages is determined 
by staining with F4/80 and CD11b antibodies, DCs were 
determined with CD11c and MHC-II antibodies.
Flow cytometry
FACS analysis were performed with routine 
protocols using the FACS Calibur flow cytometer (BD 
Immunocytometry Systems), antibodies used for mice 
spleen lymphocyte staining are as following: CD3-Percp 
cy5.5, CD4-FITC, APC, CD8-Percp cy5.5, PE, CD19-
FITC, B220-PE, CD69-FITC, CD80-FITC, CD86-APC, 
CD40-PE (Biolegend) and bone marrow staining: F4/80-
PE, CD11b-FITC, MHC-II-PerCP cy5.5 (Biolegend). 
FACS buffer; 1 × PBS (Gibco) + 2% FBS (Sigma). All 
data were analyzed using FlowJo (Tree Star, Inc.).
Mice immunization
Experiments with mice were conducted in 
compliance with a protocol approved by the Institutional 
Animal Care and Use Committee based on the Ethical 
Principles in Animal Experimentation. Specific pathogen-
free female C57BL/6 mice aged four to five weeks, were 
divided into seven groups according to immunogen, 
each group contains 12 mice. Animals were inoculated 
intraperitoneally (i.p.) with CD40L-VLP, GM-CSF-VLP, 
and undecorated HTNV-VLP respectively (100µg per 
dose and in 12 mice (n=12)). Same number of mice was 
inoculated intraperitoneally with HTNV-VLP and mouse 
CD40L (VLP+CD40L group, 100 µg HTNV-VLP and 
25ng CD40L per dose), HTNV-VLP and mouse GM-CSF 
(VLP+GM-CSF group). HTNV vaccine (β-propiolactone 
inactive HTNV viron) was subjected to equal number of 
mice (100µl per dose). Equal amounts of PBS were used 
as controls (Table 3). Blood samples were collected on 
days 0, 14 and 28, via the tail vein, for measurement of 
serum IgG. Seven days after the last inoculation, 2/3 of 
the mice in each group were euthanized. The spleen of 
each mouse was removed and splenocytes were isolated 
in order to test cytokine profiles; in adiition serum was 
collected for further immunological analysis.
Humoral immune response assay
Sera from each group of mice were assessed for 
immunoglobulin by ELISA. Full length HTNV NP or Gc 
(0.15µg) was coated to each well of 96-well plates and 
incubated at 4°C overnight. The sera were serially diluted 
with PBS from 1:20 to 1:1024 and add into NP/Gc coated 
96-well plates. After incubation at 37°C for 1h, plates 
were washed with PBST and then diluted HRP conjugated 
goat anti mouse IgG antibody was added to each well. 
Subsequently plates were incubated at 37°C for 1h and 
then washed with PBST, then TMB solution was added 
and absorbance at 450 nm was recorded. The titer was 
determined in samples that had maximum dilution still 
showing positive result.
In order to distinguish the immunoglobulin subtypes, 
full length HTNV NP (0.15µg) was coated using similar 
method above. Sera from each group of mice were diluted 
and HRP conjugated IgG to mouse IgG1, IgG2a, IgG2b, 
IgA and IgM were applied. Absorbance at 450 nm was 
assessed to determine the amount of each immunoglobulin 
subtypes.
Because HTNV do not form plaque in Vero E6 cells, 
the neutralizing ability of antibodies was measured using 
a sandwich ELISA method. Briefly, Vero E6 cells were 
grown to 60% confluence in 96-well plates. Then plates 
were pre-incubated with serial dilutions of mouse serum 
(1:80, 1:100, 1:200,1:400, 1:800 and 1:1600) together with 
HTNV (1×10-5 TCID50) at 37°C for 1h. The virus-serum 
mixture was aspirated, added along with 0.2 ml overlay 
medium, and incubated at 37°C with 5% CO2 for 10 days. 
Plates were subjected to RT/-80°C freeze-thaw cycles 3 
times and the supernatant was collected for ELISA. We 
used HTNV NP monoclonal antibody as capture antibody 
and HRP-1A8, which is an HRP conjugated HTNV NP 
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monoclonal antibody, as detecting antibody. Neutralizing 
antibody titers are defined as the maximal serum dilution 
that 3 out of 4 duplicated wells do not show positive of 
HTNV NP.
Cytokines ELISPOT assay
The cytokines, IFN-γ, IL-2, IL-4 and IL-10, from 
immunized mice were measured using ELISPOT kits 
(Mabtech), according to the manufacturer’s instructions. 
Briefly, ELISPOT 96-well plates (supplied by the kit) 
were coated with 100 µl of anti-mouse IFN-γ, anti-mouse 
IL-2, anti-mouse IL-10, or anti-mouse IL-4 (5µg/ml in 
coating buffer). The plates were washed twice and blocked 
with blocking solution for 2h. A volume of 100µl freshly 
isolated splenocytes (1× 106 cells) from the immunized 
mice were subsequently transferred to each well and 
stimulated with NP or Gn/Gc peptide pools at 37°C for 
24 h. The cells were then washed away, and a secondary 
biotinylated anti-cytokine mAb was added to each well, 
followed by a streptavidin-HRP and AEC substrate 
solution system. Finally, the spots were counted using an 
ImmunoSpot® Analyzer (Cellular Technology Ltd. USA)
Cytotoxic assay of splenocyte
Macrophages separated from healthy mice were 
infected with 100 TCID50 HTNV at 37°C for 1h, excessive 
virus was then washed away and DMEM supplemented 
with 10% FBS was added to the cells. The macrophages 
were tested by immune fluorescence to assess the 
infection rate 2d later; the HTNV infected macrophages 
were used as target cell. Splenocytes were separated from 
immunized mice and stimulated with IL-2 as well as the 
same peptides as ELISPOT assay. U shaped 96-well plates 
were used; a volume of 100 µl target cells (1× 104 cells) 
was added to each well. Then a serial of different numbers 
of splenocytes were applied to the wells (1× 106 cells, 
5× 105 cells, 2.5× 105 cells, 1.25× 105 cells). The plates 
were incubated at 37°C for 6 h, and lactate dehydrogenase 
(LDH) released was assessed. The percentage of specific 
lysis was calculated using the following formula.
Mice protection against viral challenge
Four mice from all 7 groups were injected 
intracerebrally with 100µl of infectious HTNV. Three 
days after injection, the mice were euthanized and 
tissues from heart, liver, spleen, lung, kidney and 
cerebrum were collected and divided into two halves. 
One half was weighted and triturated in PBS. The 
total protein was measured by BCA assay and all 
samples were diluted to 1mg/ml, then HTNV antigen 
was analyzed using the same ELISA method with 
neutralizing antibody assay.
Total RNA of the other half of tissue was extracted 
following manufacturer’s instructions (Axygen), 
and reverse transcripted into cDNA using a reverse 
transcription kit (Takara). Copies of HTNV S segments 
were counted through RT-PCR analysis using a SYBR 
green RT-PCR kit (Takara), and mouse GAPDH was used 
as reference.
Statistical analysis
Data were analyzed for statistical significance 
using GraphPad Prism 5 software. Percentage of flow 
cytometry was compared using one-way ANOVA, and 
data were expressed as the mean ± SEM. Statistical 
analysis of antibody titer was performed using Kruskal-
Wallis test, and titers were expressed as the geometric 
mean. Comparison of antibody subtype level were also 
using Kruskal-Wallis test. Results of ELISPOT assay 
were compared by one-way ANOVA, and CTL assay was 
compared using two-way ANOVA. Protective efficacy was 
compared using one-way ANOVA. Data was presented as 
the mean ± SEM.
=Specificcell lysis(%) experimentgroup–LDHself releaseof target cells – LDHself releaseof splenocytes
LDH maxreleaseof target cells – LDHself releaseof target cells
Table 3: Immunization dose for animal experiments
Groups Doze
CD40L-VLP 100 µg/100 µl/mouse
GM-CSF-VLP 100 µg/100 µl/mouse
VLP 100 µg/100 µl/mouse
CD40L+VLP 100 µg/100 µl+25 ng CD40L/mouse
GM-CSF+VLP 100 µg/100 µl+25 ng GM-CSF/mouse
Vaccine 10 µl+90 µl PBS/mouse
Saline 100 µl/mouse
Doze of immunization for each mouse is listed in this table. CD40L-VLP or GM-CSF-VLP stand for HTNV VLP decorated 
with CD40L or GM-CSF, CD40L+VLP or GM-CSF+VLP stand for CD40L or GM-CSF co-immunize with HTNV VLP.
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